Table Info

Table 1.

MAO-B inhibitors used to treat PD-related symptoms

Symptoms	Authors & year	Results	MAO inhibitors	Reference
Motor symptoms
Monotherapy in early PD	Mizuno et al., (2017)	The study showed improvements in UPDRS scores.	Selegiline	[26]
Supplementary treatment for severe PD	Zhang et al., (2018)	According to the study, there was a reduction in the average amount of time per day that individuals with PD experienced “OFF” periods.	Rasagiline	[31]
Non-motor symptoms
Sleep discomfort	Gallazzi et al., (2021)	The study demonstrated a noteworthy enhancement in drowsiness.	Selegiline	[33]
Fatigue symptoms	Lim et al., (2015)	According to the study, there was a significant improvement in the scores of the Modified Fatigue Impact Scale.	Rasagiline	[35]

MAO-B: monoamine oxidase-B; PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale

Declarations

Acknowledgments

The authors thank the Chettinad Academy of Research and Education for their constant support and encouragement.

Author contributions

PKCS and SMT: Writing—original draft, Writing—review & editing. RV: Conceptualization, Writing—review & editing, Supervision.

Conflicts of interest

The authors declare no conflicts of interest to report.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Mirpour S, Turkbey EB, Marashdeh W, El Khouli R, Subramaniam RM. Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism. Clin Nucl Med. 2018;43:710–4. [DOI] [PubMed]

Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548–60. [DOI] [PubMed]

Alexoudi A, Alexoudi I, Gatzonis S. Parkinson’s disease pathogenesis, evolution and alternative pathways: A review. Rev Neurol (Paris). 2018;174:699–704. [DOI] [PubMed]

Athulya RT, Jayakrishnan S, Iype T, Rajan R, Alapatt PJ. Predictors of Levo-dopa induced Dyskinesias in Parkinson’s Disease. Ann Indian Acad Neurol. 2020;23:44–7. [DOI] [PubMed] [PMC]

Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology. 2012;37:213–46. [DOI] [PubMed] [PMC]

Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future. J Parkinsons Dis. 2022;12:477–93. [DOI] [PubMed] [PMC]

Chang Y, Wang L, Li D, Lei K, Liu S. Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann Med. 2017;49:421–34. [DOI] [PubMed]

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241–8. [DOI] [PubMed]

Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, et al. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study. J Neurol. 2017;264:1254–63. [DOI] [PubMed] [PMC]

10.

Gershanik OS. Improving L-dopa therapy: the development of enzyme inhibitors. Mov Disord. 2015;30:103–13. [DOI] [PubMed]

11.

Shih JC. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy. J Neural Transm (Vienna). 2018;125:1553–66. [DOI] [PubMed] [PMC]

12.

Carradori S, Secci D, Petzer JP. MAO inhibitors and their wider applications: a patent review. Expert Opin Ther Pat. 2018;28:211–26. [DOI] [PubMed]

13.

Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45:878–94. [DOI] [PubMed]

14.

Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500–6. [DOI] [PubMed] [PMC]

15.

Carrera I, Cacabelos R. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease. Curr Neuropharmacol. 2019;17:295–306. [DOI] [PubMed] [PMC]

16.

Bainbridge JL, 2nd RLP, Ruscin JM. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Neurol Clin. 2008;26:85–96. [DOI] [PubMed]

17.

Weinreb O, Amit T, Riederer P, Youdim MBH, Mandel SA. Neuroprotective profile of the multitarget drug rasagiline in Parkinson’s disease. Int Rev Neurobiol. 2011;100:127–49. [DOI] [PubMed]

18.

Alborghetti M, Nicoletti F. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside. Curr Neuropharmacol. 2019;17:861–73. [DOI] [PubMed] [PMC]

19.

Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109–16. [DOI] [PubMed]

20.

Faustini G, Bono F, Valerio A, Pizzi M, Spano P, Bellucci A. Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease? Genes (Basel). 2017;8:377. [DOI] [PubMed] [PMC]

21.

Czerniczyniec A, Bustamante J, Lores-Arnaiz S. Modulation of brain mitochondrial function by deprenyl. Neurochem Int. 2006;48:235–41. [DOI] [PubMed]

22.

Braga CA, Follmer C, Palhano FL, Khattar E, Freitas MS, Romão L, et al. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol. 2011;405:254–73. [DOI] [PubMed]

23.

Kakish J, Tavassoly O, Lee JS. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein. ACS Chem Neurosci. 2015;6:347–55. [DOI] [PubMed]

24.

Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16:1239–52. [DOI] [PubMed] [PMC]

25.

Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, et al. Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations. J Neural Transm (Vienna). 2023;130:847–61. [DOI] [PubMed] [PMC]

26.

Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, et al. A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease. Clin Neuropharmacol. 2017;40:201–7. [DOI] [PubMed] [PMC]

27.

Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937–43. [DOI] [PubMed]

28.

Shoulson I. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. Eur Neurol. 1992;32:46–53. [DOI] [PubMed]

29.

Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S; ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord. 2014;29:1028–34. [DOI] [PubMed]

30.

Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G, Neophytides AN, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol. 1988;11:45–55. [DOI] [PubMed]

31.

Zhang Z, Shao M, Chen S, Liu C, Peng R, Li Y, et al. Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China. Transl Neurodegener. 2018;7:14. [DOI] [PubMed] [PMC]

32.

Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71:589–95. [DOI] [PubMed] [PMC]

33.

Gallazzi M, Mauri M, Bianchi ML, Riboldazzi G, Cariddi LP, Carimati F, et al. Selegiline reduces daytime sleepiness in patients with Parkinson’s disease. Brain Behav. 2021;11:e01880. [DOI] [PubMed] [PMC]

34.

Schettino C, Dato C, Capaldo G, Sampaolo S, Iorio GD, Melone MA. Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study. Neuropsychiatr Dis Treat. 2016;12:2497–502. [DOI] [PubMed] [PMC]

35.

Lim TT, Kluger BM, Rodriguez RL, Malaty IA, Palacio R Jr, Ojo OO, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord. 2015;30:1825–30. [DOI] [PubMed]

36.

Seppi K, Chaudhuri KR, Coelho M, Fox SH, Katzenschlager R, Lloret SP, et al.; the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34:180–98. [DOI] [PubMed] [PMC]

37.

Liu J, Xu F, Nie Z, Shao L. Gut Microbiota Approach-A New Strategy to Treat Parkinson’s Disease. Front Cell Infect Microbiol. 2020;10:570658. [DOI] [PubMed] [PMC]

38.

Liu C, Zhang X, Zhou L, Wang T, Quan Z, Zhang Y, et al. Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. Neurogastroenterol Motil. 2018;30:e13390. [DOI] [PubMed]

39.

Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, et al. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology. 2015;40:650–7. [DOI] [PubMed] [PMC]

40.

Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É. Selegiline: a molecule with innovative potential. J Neural Transm (Vienna). 2020;127:831–42. [DOI] [PubMed] [PMC]

41.

Moore JJ, Saadabadi A. Selegiline. Treasure Island (FL): StatPearls Publishing; 2023.

42.

Jiang D, Li M, Jiang L, Chen X, Zhou X. Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson’s disease: a meta-analysis. Aging Clin Exp Res. 2020;32:769–79. [DOI] [PubMed]

43.

Rogers G, Davies D, Pink J, Cooper P. Parkinson’s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951. [DOI] [PubMed]

44.

Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004;329:593. [DOI] [PubMed] [PMC]

45.

Hattori N, Takeda A, Takeda S, Nishimura A, Kitagawa T, Mochizuki H, et al. Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease. J Neural Transm (Vienna). 2019;126:299–308. [DOI] [PubMed] [PMC]

46.

Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34:1250–8. [DOI] [PubMed]

47.

Naoi M, Maruyama W, Shamoto-Nagai M. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease. J Neural Transm (Vienna). 2020;127:131–47. [DOI] [PubMed]

48.

Jiang Y, Zhang X, Mu H, Hua H, Duan D, Yan X, et al. Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease. Drug Deliv. 2018;25:143–52. [DOI] [PubMed] [PMC]

49.

Yeung AWK, Georgieva MG, Atanasov AG, Tzvetkov NT. Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. Front Mol Neurosci. 2019;12:143. [DOI] [PubMed] [PMC]

50.

Carradori S, Ortuso F, Petzer A, Bagetta D, Monte CD, Secci D, et al. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. Eur J Med Chem. 2018;143:1543–52. [DOI] [PubMed]

51.

Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, et al.; RAS-ALS Study Group. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17:681–8. [DOI] [PubMed]